Research progress on the pharmacological effects of berberine targeting mitochondria

Xinyi Fang1,2, Haoran Wu2, Jiahua Wei3, Runyu Miao1,2, Yanjiao Zhang1 and Jiaxing Tian1*

1Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Graduate College, Beijing University of Chinese Medicine, Beijing, China, 3Graduate College, Changchun University of Chinese Medicine, Changchun, China

Berberine is a natural active ingredient extracted from the rhizome of Rhizoma Coptidis, which interacts with multiple intracellular targets and exhibits a wide range of pharmacological activities. Previous studies have preliminarily confirmed that the regulation of mitochondrial activity is related to various pharmacological actions of berberine, such as regulating blood sugar and lipid and inhibiting tumor progression. However, the mechanism of berberine’s regulation of mitochondrial activity remains to be further studied. This paper summarizes the molecular mechanism of the mitochondrial quality control system and briefly reviews the targets of berberine in regulating mitochondrial activity. It is proposed that berberine mainly regulates glycolipid metabolism by regulating mitochondrial respiratory chain function, promotes tumor cell apoptosis by regulating mitochondrial apoptosis pathway, and protects cardiac function by promoting mitophagy to alleviate mitochondrial dysfunction. It reveals the mechanism of berberine’s pharmacological effects from the perspective of mitochondria and provides a scientific basis for the application of berberine in the clinical treatment of diseases.

KEYWORDS
berberine, mitochondria, pharmacological action, glycolipid metabolism disorder, tumor, cardiovascular diseases

Introduction

Recent studies have found that berberine, an active ingredient from traditional Chinese medicine, has various medicinal effects. Berberine is not only irreplaceable for its dominance of antibacterial, anti-inflammatory and antiviral in traditional pharmacological research, but also has become a current research hotspot because of its remarkable curative effect in the treatment of tumors, diabetes, cardiovascular diseases, and digestive system disease. Although the pharmacological effects of berberine have been confirmed in clinical patients and animal models in the past
decade, its specific targets and mechanism of action on the body are still unclear, which limits its further wide application and promotion in clinical practice. Mitochondria are organelles that exist in most cells and are involved in maintaining the stability of the internal environment by producing reactive oxygen species (ROS) and regulating cellular metabolism. A large number of studies have shown that mitochondria are one of the important targets for berberine to exert its pharmacological effects, but its specific mechanism needs to be further studied. Based on this, this paper intends to systematically review the research progress of berberine in improving glycolipid metabolism disorder, anti-tumor, and treating cardiovascular disease by regulating mitochondria, in order to provide a reference for elucidating the pharmacological mechanism of action of berberine.

The pharmacokinetics and toxicology of berberine

Berberine is a natural isoquinoline alkaloid with yellow needle-like crystals in appearance, mostly in stable forms of hydrochloride and sulfate (1). Modern pharmacological research showed that berberine has inhibitory effects on a variety of gram-positive and gram-negative bacteria, and its mechanism of action may be to selectively inhibit bacterial RNA transcription, protein/lipid biosynthesis, and glycolysis. Berberine is mainly used to treat bacterial infectious diseases such as bacillary dysentery, gastroenteritis and carbuncle (2). With in-depth research, berberine has been found to have other extensive pharmacological actions, such as anti-oxidation, blood sugar and blood lipid regulation, anti-tumor, treatment of cardiovascular disease, etc. These new findings expand the range of applications of berberine (3, 4).

The source of berberine

Berberine mainly exists in Ranunculaceae, Berberaceae, Papaveraceae, Rutaceae, Fangchiaceae, Rhamnaceae and other plants, with the highest content in Rhizoma Coptidis and Phellodendron. It can be extracted by acid water extraction, alkaline water extraction, ethanol extraction, liquid membrane method, two-phase extraction, supercritical fluid extraction, etc. Plant extraction and isolation, tissue culture, biological fermentation and chemical synthesis are the main ways to obtain berberine. Among them, chemical synthesis is the most important and direct source. At present, the generally accepted mainstream pathway of berberine biosynthesis is L-tyrosine as the starting material, which is converted into dopamine and 4-hydroxyphenylacetaldehyde, respectively, and then the skeleton is synthesized by biological enzymes such as synthase and transferase, and finally converted into natural berberine after skeleton modification.

Pharmacokinetic study of berberine

The bioavailability of berberine is closely related to the route of administration. According to the experimental data, the bioavailability of berberine decreases in the following order of administration routes: intravenous injection, intraperitoneal injection, intragastric oral administration (5). Oral administration of berberine has the characteristics of difficult absorption, rapid metabolism and low blood concentration. Berberine has poor intestinal absorption and low bioavailability after oral administration. The study (6) found that the peak plasma concentration (Cmax) of berberine after oral administration of 40mg·kg⁻¹ in rats was only 10µg·L⁻¹.

There are two main reasons for the low bioavailability of berberine. One is that berberine is a quaternary ammonium base with a lipid-water partition coefficient of -1.5. Drugs containing quaternary ammonium groups in the structure have strong hydrophilicity and low ability to penetrate cell membranes, which limit the transmembrane transport and intestinal absorption of drugs (7). Second, berberine is a substrate of P-glycoprotein (P-gp) (8). The P-glycoprotein is located on the cell membrane and acts as a drug efflux pump, and its transport leads to the secretion of absorbed berberine back into the intestine. In terms of clinical medication, although intravenous injection can increase the drug concentration in the blood, clinical trials found that it will cause serious side effects (e.g., drop in blood pressure and respiratory arrest). Thus, oral administration is the main clinical berberine administration method (9).

The uptake and distribution of berberine in tissues are very important for its biological activity. Studies have shown that berberine is widely distributed in the body after rapid absorption, and the liver is the main organ for the distribution of berberine. Tan et al. (10) deeply studied the organ distribution of berberine in rats, and the results showed that berberine (200mg·kg⁻¹, orally) was rapidly distributed in major organs, such as the liver, kidney, muscle, lung, brain, heart, pancreas and fat. Ma et al. (11) determined the dose-related tissue concentration of the Rhizoma Coptidis alkaloids in mice using high-performance liquid chromatography with ultraviolet detection. The research indicated that four Rhizoma Coptidis alkaloids were detected in the brain, heart, and lung tissues of mice that received the oral total extract of Rhizoma Coptidis. Berberine can also penetrate the blood-brain barrier (12). Liu et al. (13) administered berberine to rats by gavage and found that the distribution of berberine in the liver was 70 times the exposure in the blood. Berberine and its metabolites are widely distributed in tissues and remain relatively stable, which may be
the reason they are still active in the body even at low blood concentrations, and can still exert good antibacterial, anti-inflammatory, and hypoglycemic effects.

The main site of berberine metabolism in the body is the liver, which can be rapidly metabolized by a variety of P450 enzymes in the liver. The main metabolic pathway of phase I is methylation and demethylation, and the phase II metabolic pathway is glucuronidation and sulfation. At the same time, after berberine enters the body via oral administration, it will inevitably come in contact with gut microbiota. Gut microbiota can produce a variety of enzymes, such as glycosidase, nitroreductase, etc. Biotransformation of gut microbiota regulates berberine absorption and metabolism in vivo. Studies have shown that nitroreductase produced by gut microbiota is an important biological factor that positively regulates the intestinal absorption and metabolism of berberine. Berberine, which is not easily absorbed by the gut, can be converted into dihydroberberine by the nitroreductase produced by gut microbiota, and then the dihydroberberine enters the intestinal wall, where it is oxidized to berberine in the intestinal wall tissue, finally enters the blood circulation (14). In addition, the gut microbiota also plays an important role in the enterohepatic circulation of berberine metabolites. Therefore, both liver and gut microbiota are involved in the metabolism of berberine in vivo.

Berberine is mainly excreted in the urine and bile in animals, with less excretion in the stool. There is still a lack of human sample studies on the excretion kinetics of berberine. MA et al (15) studied the excretion kinetics of berberine after oral administration in rats and found that berberine was mainly excreted in the form of phase I metabolites in bile and urine.

Toxicology study of berberine

The toxic effects of berberine are usually expressed as median lethal dose (LD₅₀), which varies with the biological species and route of administration. Berberine acute toxicity test showed that the dose of dead mice after intragastric administration was 83.2 g·kg⁻¹, while the LD₃₀ after intravenous administration was 9.04 mg·kg⁻¹. It is not known whether the bioavailability of oral administration is significantly different from that of intravenous administration. It is worth noting that no matter how different the doses of berberine administered by different routes are, the blood concentration of berberine at the time of mouse death is not different, about 0.5-0.7 mg·L⁻¹. It is suggested that the toxicity of berberine is affected by its blood concentration (5). Emerging studies have shown that berberine is almost safe at conventional doses, with a relatively low incidence of adverse reactions, such as gastrointestinal discomfort, and transient increases in plasma bilirubin levels (16). Although berberine is relatively safe, it should be used with caution in specific circumstances to avoid adverse reactions. For example, A mouse study found that administration of berberine (5 mg/kg) could induce skeletal muscle atrophy via increasing atrogin-1 expression (17), whether this effect extends to humans is not currently known.

Berberine can be toxic to nerve cells by affecting the mitochondrial respiratory chain and N-methyl-D-aspartic acid receptors (18). Berberine replaces bilirubin in binding to albumin, suggesting that the use of the herb and other traditional Chinese medicines containing a high proportion of berberine is best avoided in jaundiced neonates and pregnant women (19). Berberine interacts with macrolides to inhibit human ether-a-go-go-related gene (hERG) channels, leading to arrhythmias (20). Berberine in combination with statins increases cardiotoxicity by inhibiting CYP3A4 and hERG potassium channels (21).

Research progress on the regulation mechanism of mitochondrial activity

Mitochondria are an important organelle ubiquitous in eukaryotic cells. They are mainly divided into the outer membrane, intermembrane space, inner membrane and matrix. Different enzymes and biological factors are distributed in different spaces. For example, there are anti-apoptotic Bcl-2 family proteins and ion channel proteins on the outer membrane, cytochrome C, apoptosis-inducing factor and procaspase 2, 3, and 9 are distributed in the intermembrane space, the inner membrane is the aggregation site of the complexes that make up the mitochondrial respiratory chain complex enzymes, the tricarboxylic acid cycle-related enzymes and mitochondrial genome are distributed in the matrix. The difference in the permeability of the inner and outer mitochondrial membranes creates a trans-mitochondrial membrane potential that maintains mitochondrial integrity and performs its normal function. Mitochondria are important places for cells to perform aerobic respiration and oxidative phosphorylation to synthesize ATP. Furthermore, mitochondria are also involved in various physiological processes such as cell proliferation, differentiation, signal transduction, innate immune regulation, autophagy, and apoptosis (22). As a highly dynamic organelle, mitochondria are precisely regulated by a variety of proteins for mitochondrial fusion, fission, biosynthesis and clearance (mainly mitophagy) to ensure that mitochondria function effectively, adapt to the energy metabolism of cells, and maintain cells in various physiological activity (Figure 1).

Regulatory mechanisms of mitochondrial dynamics

Mitochondrial dynamics refers to the continuous fission and fusion of mitochondria to control mitochondrial morphology, provide energy for cells, and regulate processes such as
autophagy, calcium homeostasis, innate immunity, signal transduction, and apoptosis (23). Mitochondrial fission is a proliferative process that produces one or more daughter mitochondria, which are required for the formation of new mitochondria. Mitochondrial fission not only increases the number of mitochondria, but also separates damaged mitochondria from the mitochondrial network and promotes autophagy of damaged mitochondria (24). Mitochondrial fusion is a phenomenon in which two adjacent mitochondrial outer and inner membranes fuse to form a mitochondrion with a fibrous extension and a network-like structure. Mitochondrial fusion is important for maintaining normal mitochondrial function. When mitochondria are slightly damaged, mitochondria fuse, which can maintain the stability of the mitochondrial structure, allow material exchange between mitochondria, and repair their functional defects. The dynamic balance of mitochondrial fission and fusion is crucial to maintaining the quality and function of mitochondria, and is an important basis for ensuring the normal activities of cells. Enhanced or weakened mitochondrial fission/fusion protein functions can disrupt the mitochondrial dynamic balance, which may lead to oxidative stress, mitochondrial dysfunction and metabolic changes, and ultimately promote the occurrence of related diseases.

Mitochondrial fission is mainly regulated by mitochondrial dynamin-related protein 1 (Drp1) and Drp1 receptor proteins located in the inner or outer mitochondrial membrane, such as mitochondrial fission factor (MIF), mitochondrial fission protein 1 (Fis1), mitochondrial dynamics proteins of 49 kDa (MiD49) and mitochondrial dynamics proteins of 51 kDa (MiD51) (25). Drp1 is a protein necessary for mitochondrial fission. It is generally located in the cytoplasm under physiological conditions. It is mainly composed of an N-terminal GTPase effector domain (26). Under the stimulation of various mitochondrial fission factors, Drp1 is recruited to mitochondria by its receptor protein, oligomerization occurs, and multiple Drp1 assemble into cyclic polymers around mitochondria. Under the action of GTPase hydrolysis, Drp1 cyclic polymers shrink, which ruptures the inner and outer mitochondrial membranes, eventually leading to mitochondrial fission (27). After mitochondrial fission, Drp1 can revert to monomers and re-enter the cytoplasm for reuse (28).

Mitochondrial fusion includes three steps, mitochondrial tethering, mitochondrial outer membrane fusion, and mitochondrial inner membrane fusion (29). In mammals, it is mainly regulated by mitofusin 1 (Mfn1), mitofusin 2 (Mfn2) and optic atrophy 1 (OPA1) protein (30). Among them, Mfn1 and Mfn2 mainly mediate mitochondrial outer membrane fusion, and OPA1 mainly participates in the mitochondrial inner membrane fusion process. Mfn is widely expressed on the outer mitochondrial membrane, and the interaction between Mfn1 and Mfn2 undergoes cis dimerization to form Mfn1/Mfn2 homodimers or Mfn1-Mfn2 heterodimers, which promote the occurrence of adjacent mitochondrial outer membranes tethering and subsequent mitochondrial outer membrane fusion (31, 32). Next, OPA1, which localizes to the inner mitochondrial membrane, mediates mitochondrial inner membrane fusion and cristae remodeling (33). Studies have shown that OPA1 induces mitochondrial inner membrane fusion in a manner dependent on Mfn1, but not Mfn2, suggesting that there may be information transmission between the inner and outer membranes during mitochondrial fusion, and there may be an interaction between the outer membrane protein Mfn1 and the inner membrane protein OPA1 (34). However, the mechanism of OPA1-induced mitochondrial inner membrane fusion has not been fully revealed, and more in-depth studies are still needed.
Regulatory mechanism of mitophagy

Mitophagy refers to the depolarization of mitochondria in cells under stress such as ROS, nutrient deficiency, and cell aging. The damaged mitochondria are specifically encapsulated into autophagosomes and fused with lysosomes to complete the process of degradation of damaged mitochondria, thereby maintaining a stable intracellular environment (35). Mitophagy not only removes damaged mitochondria, but also degrades normal mitochondria for survival when cells are in a harsh environment (36). Mitophagy is a type of selective autophagy that controls the quantity and quality of mitochondria and maintains the normal function of the mitochondrial network. Abnormal mitophagy can cause many pathological changes, which can lead to Alzheimer’s disease, Parkinson’s disease, heart failure, tumors and other diseases.

Mitophagy in mammalian cells mainly includes the ubiquitination degradation pathway mediated by PTEN-induced putative kinase protein 1 (PINK1) and the receptor recognition pathway mediated by different proteins such as Nip3-like protein X (NIX), Bcl-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3), FUN14 domain-containing protein 1 (FUNDCL1), FK506 binding protein 8 (FKBP8), Bcl-2-like protein 3 (BCL2L13), nucleotide-binding domain and leucine-rich-repeat-containing proteins X1 (NLRX1), prohibitin-2 (PHB2) and cardiolipin (CL). Parkin is an E3 ubiquitin ligase present in the cytoplasm (37), and PINK1 is a prohibitin-2 (PHB2) and cardiolipin (CL). Parkin is an E3 ubiquitin ligase present in the cytoplasm (37), and PINK1 is a mitochondrial serine/threonine kinase. Studies have confirmed that PINK1 is an upstream regulatory protein of Parkin, and the two synergistically mediate the polyubiquitination process of damaged mitochondrial surface structures or functional proteins, and play a key role in depolarizing mitophagy degradation (38). Recent studies have shown that PINK1 can also induce mitophagy in a Parkin-independent manner. PINK1 recruits LC3 adaptor proteins OPTN and NDP52 to mitochondria, which in turn recruits autophagy initiator UNC-51-like kinase 1 (ULK1), double FYVE containing protein 1 (DFCP1), and WD repeat domain phosphoinositide-interacting protein 1 (WIPI1) to induce mitophagy (39). Additionally, synphilin-1 overexpression recruits PINK1, and the PINK-synphilin-1 complex can further recruit the E3 ubiquitin ligase SIAH-1 and promote the ubiquitination of mitochondrial proteins to induce mitophagy (40). NIX and BNIP3 are localized in the outer mitochondrial membrane (OMM) and belong to the BH3-only subfamily of B cell lymphoma-2 (Bcl-2) family proteins. NIX and BNIP3 can directly bind to LC3 through their BH3 domains to induce mitophagy (41, 42). Under hypoxic conditions, the mitochondrial outer membrane protein FUNDCL1 induces mitophagy in a Parkin-independent manner by directly binding to LC3 (43). The activity of FUNDCL1-induced mitophagy is regulated by phosphorylation and ubiquitination modifications (44, 45). BCL2L13 in the mammalian cell is a homologue of Atg32 in the yeast cell. Atg32 is the only mitophagy receptor molecule in yeast cells. BCL2L13 induces mitophagy through a Parkin-independent mechanism, and its mitophagy-inducing activity is regulated by phosphorylation modifications (46). FKBP8 is localized to the mitochondrial outer membrane and can bind to LC3A through its LIR amino acid sequence to mediate mitophagy, and this effect is independent of the PINK1/Parkin pathway (47). NLRX1 is a member of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family, and its N-terminus contains a mitochondrial localization sequence, making it the only NLR family mitochondrial protein (48). NLRX1 has been identified as a new mitophagy receptor involved in mitophagy (49), but its specific activation pathway and molecular mechanism have not been fully clarified. So far, the roles of many OMM proteins in mediating mitophagy have been confirmed, but the regulatory roles of inner mitochondrial membrane (IMM) proteins in mitophagy have not been fully elucidated. Recent studies have observed that PHB2 localized to the IMM is also a receptor protein that mediates mitophagy during stress and embryonic development (50). In addition, as a characteristic phospholipid of IMM, CL is involved in lipid-protein interactions and is one of the necessary raw materials for maintaining mitochondrial functions (eg, cristae formation, membrane fusion, etc.) (51). The study found that CL is a mitophagy receptor, and mitochondrial damage or membrane depolarization can cause CL to translocate from IMM to OMM, which is the initiation signal of CL-mediated mitophagy (52, 53).

Regulatory mechanisms of mitochondrial biosynthesis

Mitochondrial biogenesis refers to the process of mitochondrial proliferation and mitochondrial system synthesis and individual synthesis in the life cycle of a cell (54). Mitochondrial biosynthesis is a self-protection mechanism initiated after tissue cells are attacked. Under the synergistic effect of mitochondrial genes and nuclear genes, mitochondrial biosynthesis maintains the stability of its own structure, function and quantity by synthesizing and replacing abnormal mitochondria, ensuring the normal metabolic process of cell mitochondria (55). Under physiological conditions, mitochondrial biosynthesis increases with cell proliferation, while under stress conditions such as low temperature, exercise, oxidative stress, and inflammation, mitochondrial biosynthesis is more pronounced, which can reduce the cell damage caused by ROS while ensuring the body’s extra energy demand (56). Therefore, mitochondrial biosynthesis can not only ensure the internal balance of mitochondria, but also enhance the cells’ anti-infection and anti-oxidation capabilities.
Mitochondrial biosynthesis includes the synthesis of the mitochondrial inner membrane, outer membrane and encoded proteins, the synthesis and transfer of nuclear gene-encoded proteins, and the replication of mitochondrial DNA (mt DNA) (57). This process is regulated by a variety of factors, among which peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)/nuclear respiratory factors (NRFs)/mitochondrial transcription factor A (TFAM) signaling pathway is the most important pathway known to regulate mitochondrial biosynthesis. Overexpression of PGC-1α can increase the steady-state level of mt DNA, NRF-1/2 as a downstream transcription factor target of PGC-1α, is a major transcriptional regulator linking nuclear-encoded genes and mitochondrial biosynthesis, NRF-1/2 and PGC-1α bind and co-activates, while NRF-1/2 is involved in the expression of mt DNA-encoded mitochondrial proteins (58). TFAM is required for mt DNA transcription and replication, and binds to mitochondrial promoter sequences (including heavy and light chain specific promoters) in a sequence-specific manner, thereby efficiently activating mt DNA transcription. In conclusion, once PGC-1α is activated by the upstream adenosine 5’monophosphate-activated protein kinase (AMPK) and deacetylase through phosphorylation and deacetylation, it can bind to and help activate the downstream NRF-1/2, and then bind to the TFAM promoter to activate TFAM, complete and promote the replication and transcription of mt DNA for mitochondrial biosynthesis (59).

Pharmacological effects of berberine targeting the mitochondria

The targeting mechanism of berberine exerting its pharmacological effects is complex. Previous studies have found that the regulation of mitochondrial activity is one of the ways that berberine exerts its pharmacological action (Figure 2, Table 1). Exploring the mechanism of berberine targeting the mitochondria has a certain guiding significance for promoting the clinical application of berberine.

Regulate glycolipid metabolism

The relationship between mitochondria and the development of glycolipid metabolism disorder

Mitochondria, as the hub of body energy metabolism, are closely related to the occurrence and development of glycolipid metabolism disorder. Oxidative damage caused by mitochondrial ROS production plays a key role in the pathogenesis of glycolipid metabolism disorder, and is also an important pathophysiological feature of glycolipid metabolism disorder. In the respiratory electron transport chain, an appropriate amount of ROS can promote the secretion of insulin from islet β cells. However, patients with glycolipid metabolism disorder are exposed to a chronic state of hyperglycemia, causing oxidative stress damage to β cells and inhibiting β cell function and survival. Fluctuations in mitochondrial transmembrane potential can cause changes in intracellular adenosine triphosphate (ATP)/adenosine diphosphate (ADP) ratio and affect insulin secretion. Uncoupling protein 2 (UCP2), which is located in the inner mitochondrial membrane, is the master mitochondrial regulator of insulin secretion, and can cause proton leakage, decreased mitochondrial transmembrane potential, uncoupling of oxidative phosphorylation, and decreased ATP production, ultimately leading to a decrease in insulin secretion by β cells (89). Reduced mitochondrial biosynthesis is closely related to insulin resistance. Studies have shown that reduced mitochondria number and volume, and impaired mitochondrial respiration...
# TABLE 1  
Research progress on the pharmacological effects of berberine targeting mitochondria.

| Effect | Experimental Model | Activities related to mitochondria | Ref. |
|--------|-------------------|-----------------------------------|------|
| **Glycolipid metabolism disorder** | Promote glycolysis | Human hepatoma cell line HepG2 and mouse skeletal myoblast C2C12 | Inhibit mitochondrial respiratory chain complex I, suppress ATP synthesis and enhance glycolysis. | (60) |
| | Improve insulin sensitivity | LKB1<sup>−/−</sup> mouse embryonic fibroblasts and L6 myotubes, HFD-induced C57Bl/6j mice | Inhibit mitochondrial respiratory chain complex I, activate AMPK and improve systemic insulin sensitivity. | (61) |
| | Inhibit gluconeogenesis | Primary hepatocytes from adult mice, ICR mice | Inhibit SIRT3, induce mitochondrial dysfunction, increase AMPK-related glucose uptake, block glucagon signaling and degrade its downstream target PEPCK1, thereby inhibiting gluconeogenesis. Preserve MPC1 acetylation by SIRT3 inhibition, and block mitochondrial pyruvate supply for gluconeogenesis due to MPC1 protein degradation. | (62, 63) |
| | Promote secretion of GLP-1 | DIO mice | Inhibit ATP overproduction, control mitochondrial stress, protect intestinal L cells and promote GLP-1 secretion. | (64) |
| | Improve lipid metabolism | db/db mice, HFD-induced KO mice, C2C12 myoblasts | Upregulate the mitochondrial content in brown and white adipocytes, stimulate UCP1-mediated thermogenesis, and accelerate fat catabolism. Alleviate HFD-induced inhibition of mitochondrial β-OX through SIRT3-mediated LCAD deacylation, and improve nonalcoholic fatty liver disease. Promote mitochondrial biosynthesis, improve fatty acid oxidation in an AMPK/PGC-1α-dependent manner and decrease abnormal ectopic lipid deposition in skeletal muscle. | (65–67) |
| Others | HFD-induced Sprague Dawley rats, conditionally immortalized mouse podocyte, db/db mice | Improve mitochondrial biosynthesis and function via SIRT1-mediated mechanism. Activate the PGC-1α signaling pathway, and promote mitochondrial energy homeostasis and fatty acid oxidation. Inhibit the expression and translocation of Drp1, improve the fragmentation and dysfunction of mitochondria and reverse glycolipid metabolism disorder. | (68–70) |
| **Antitumor** | Induce tumor cell apoptosis | Pancreatic cancer cells, glioma cells, thyroid carcinoma cells, HepG2 cells, EBV-transformed B cells | Induce mitochondrial damage, target and regulate citrate metabolism and membrane transport in mitochondria, interfere with the synthesis and expression of downstream fatty acids and promote cancer cells apoptosis. Inhibit ERK activity, induce mitochondrial dysfunction, and lead to ATP depletion. Induce mitochondrial apoptosis, G0/G1 cell cycle arrest and suppress migration via PI3K-AKT and MAPK signaling pathways. Increase the production of ROS, activate the MAPK-p53 signaling pathway, and disrupt mitochondrial potential. Up-regulate the expression of FoxO1 and FoxO3, heighten BH3-only protein Bim expression, alter Bax/Bcl-2 ratio and induce mitochondrial dysfunction. | (71–75) |
| | Inhibit tumor cell proliferation | HepG2 xenograft model (CD1-nude mice were injected with HepG2 cells at a concentration of 10⁶ cells per mouse) | Decrease mtDNA copy number of tumor cells and inhibit cell proliferation. | (76) |
| **Protect cardiovascular system** | Improve myocardial ischemia/reperfusion injury | H9C2 cardiomyocytes | Activate HIF-1α/BNIP3 or PINK1-Parkin signaling pathway, promote mitophagy, reduce mitochondrial dysfunction, and improve myocardial I/R injury. | (77, 78) |
| | Inhibit cardiomyocyte apoptosis | Neonatal rat cardiomyocytes, Sprague-Dawley rats | Protect mitochondria (reduce mitochondrial membrane potential), increase the ratio of AMP to ATP and inhibit AMPK phosphorylation, elevate Bcl-2 expression, and suppress DOX-induced cardiomyocyte apoptosis. | (79) |
| | Improve cardiomyocyte hypertrophy | H9C2 cells | Activate the AMPK signaling pathway to inhibit mitochondrial fission, upregulate PGC1α to stimulate mitochondrial biogenesis, restore autophagic flux disturbance, and prevent high glucose-induced cardiomyocyte hypertrophy. | (80) |
| Others | C57BL/6J mice | Activate mitophagy via the PINK1/Parkin pathway and protect cardiac function in pressure overload-induced heart failure. | (81) |

(Continued)
Mitochondrial damage plays an important role in the pathogenesis of glycolipid metabolism disorder, and mitochondrial dysfunction and glycolipid metabolism disorder have mutually causal relationships, forming a vicious circle. Mitochondrial membrane potential hyperpolarization, abnormal expression of uncoupling protein 2, reduced mitochondrial biosynthesis, and mitochondrial autophagy impairment lead to impaired mitochondrial function or structure, resulting in excessive production of ROS and aggravating insulin resistance. At the same time, mitochondrial gene variation is associated with the susceptibility to glycolipid metabolism disorder. Therefore, regulating mitochondrial biosynthesis and mitophagy, improving mitochondrial function, and mitochondrial gene therapy might be effective strategies to improve insulin resistance and prevent or delay glycolipid metabolism disorder.

Research progress of berberine in regulating glycolipid metabolism disorder by targeting the mitochondria

As the core mechanism of metabolic diseases such as diabetes, obesity and dyslipidemia, glycolipid metabolism disorder is quietly threatening human health. Previous studies have found that berberine can increase the expression of insulin receptors, promote glycosylation, enhance insulin sensitivity, promote the release and secretion of insulin, increase the consumption of glucose by liver cells, inhibit the differentiation of adipocytes, and regulate gut microbiota to regulate glycolipid metabolism, reduce triglyceride, cholesterol, low-density lipoprotein and blood glucose levels (95–97).
Mitochondria are essential for maintaining energy metabolism. A large amount of literature have reported that berberine inhibits hepatic gluconeogenesis, promotes the secretion of glucagon-like peptide-1 (GLP-1), upregulates glycolysis, enhances insulin sensitivity, and improves fatty acid oxidation by regulating mitochondrial activity, thereby regulating glycolipid metabolism. Xu et al. reported that elevated glycolysis may be a primary cause increased glucose consumption in hepatocytes and myotubes by berberine. In vitro experiment proved that berberine inhibited mitochondrial respiratory chain complex I, which led to the suppression of ATP synthesis, the enhancement of glycolysis, and the promotion of glucose metabolism, a process independent of AMPK activation (60). The results of animal experiments showed that berberine upregulates the mitochondrial content in brown and white adipocytes in db/db mice, and stimulates uncoupling protein 1 (UCP1)-mediated thermogenesis, thereby accelerating fat catabolism and improving obesity and other abnormal lipid metabolism diseases (65). Gomes et al. found that berberine improved mitochondrial biosynthesis and function via a silent mating type information regulation 2 homolog 1 (SIRT1)-mediated mechanism, thereby protecting against the deleterious effects of high-fat diet (HFD) feeding, hyperglycemia and fatty acids (68). Early studies found that berberine has direct inhibition of mitochondrial respiratory chain complex I, inhibiting mitochondrial oxidative respiration, increasing intracellular adenosine monophosphate (AMP)/ATP, thereby activating AMPK and improving systemic insulin sensitivity (61). Zhang et al. found that berberine inhibited mitochondrial function by inhibiting SIRT3. SIRT3 is a soluble protein deacetylase located in the mitochondrial matrix. It can interact with the subunits of the mitochondrial respiraory chain complex I, inhibiting mitochondrial oxidative respiration, increasing intracellular adenosine monophosphate (AMP)/ATP, thereby activating AMPK and improving systemic insulin sensitivity (61). Zhang et al. found that berberine inhibited mitochondrial function by inhibiting SIRT3. SIRT3 is a soluble protein deacetylase located in the mitochondrial matrix. It can interact with the subunits of the mitochondrial respiration Complex I. SIRT3 regulates the function of Complex I in the electron transport chain and maintains basal ATP yield. Inhibition of SIRT3 by berberine leads to mitochondrial dysfunction and increases the ratio of AMP/ATP, resulting in activating AMPK signaling, increasing AMPK-related glucose uptake, blocking glucagon signaling and degrading its downstream target PEPCK1, thereby inhibiting gluconeogenesis (62). Li et al. revealed that berberine reduced fasting hyperglycemia by reducing mitochondrial pyruvate import via inhibiting MPC1 function in the setting of lipid overload. Mitochondrial pyruvate import via mitochondrial pyruvate carrier (MPC) is a central step in hepatic gluconeogenesis. Berberine reduced hepatic acetyl CoA accumulation by limiting fatty acid oxidation and preserved MPC1 acetylation by SIRT3 inhibition, eventually blocking mitochondrial pyruvate supply for gluconeogenesis due to MPC1 protein degradation (63). However, recent studies identified that berberine can also regulate lipid metabolism by activating SIRT3. Inhibition of mitochondrial β-oxidation (β-OX) has been reported to be involved in the pathogenesis of the nonalcoholic fatty liver disease. SIRT3 regulates mitochondrial β-OX by deacetylating its substrate long-chain acyl-CoA dehydrogenase (LCAD). Xu et al. reported that berberine could alleviate HFD-induced inhibition of mitochondrial β-OX through SIRT3-mediated LCAD deacetylation, thereby improving nonalcoholic fatty liver disease in mice (66). Sun’s study showed that berberine controlled mitochondrial stress by inhibiting ATP overproduction in diet-induced obesity mice, thereby protecting intestinal L cells and promoting GLP-1 secretion (64). Yao et al. explored the effect of berberine on skeletal muscle lipid deposition and mitochondrial function from in vivo and in vitro experiments, and found that berberine could significantly reduce the content of triglycerides in the gastrocnemius muscle of obese mice, and it could promote mitochondrial biogenesis and decrease abnormal ectopic lipid deposition in skeletal muscle by improving fatty acid oxidation in an AMPK/PGC-1α-dependent manner (67). Qin et al. found that berberine ameliorated fatty acid oxidation and related metabolic disorders in podocytes of diabetic kidney disease (DKD) mice by promoting PGC-1α to regulate mitochondrial energy homeostasis (69). Berberine activated the PGC-1α signaling pathway, which promoted mitochondrial energy homeostasis and fatty acid oxidation in podocytes. Lipid accumulation, excessive generation of mitochondrial ROS, mitochondrial dysfunction, and deficient fatty acid oxidation in DKD mouse models and cultured podocytes were suppressed by berberine. In addition, through inhibiting the expression and translocation of Drp1, berberine potently improved the fragmentation and dysfunction of mitochondria in podocytes, reduced mesangial matrix expansion, glomerular basement membrane thickening, podocyte damage, albuminuria and metabolic abnormalities of DKD (70).

**Antitumor**

**The relationship between mitochondria and tumorigenesis**

The occurrence and development of tumors is a complex biological process involving multiple genes and multiple signaling pathways. Compared with normal cells, tumor cells have the characteristics of infinite proliferation, abnormal energy metabolism, increased ROS, tissue infiltration and metastasis, and resistance to cell death (98). In recent years, people have gradually realized that mitochondrial energy metabolism, oxygen free radical homeostasis, calcium ion homeostasis, apoptosis and autophagy abnormalities, and impaired mitochondrial dynamics play important roles in tumorigenesis, and proposed a new strategy for tumor therapy targeting the mitochondria.

The energy metabolism of tumor cells is significantly different from that of normal cells, and their rapid proliferation requires a large amount of biological
macromolecules such as carbohydrates, lipids, and proteins. Mitochondria are the most important organelles that regulate cell metabolism. Abnormal mitochondrial metabolism is closely related to the proliferation, metastasis and survival of tumor cells (99). Tumor cells rely mainly on aerobic glycolysis to generate ATP instead of more efficient mitochondrial oxidative phosphorylation (100). The main reason might be that the mitochondrial function of tumor cells is irreversibly damaged, and oxidative phosphorylation is inhibited. This is the famous Warburg effect, which is one of the unique metabolic characteristics of tumor cells. Glycolysis not only provides energy for the life activities of tumor cells, but its intermediate metabolites can also provide carbon precursors for the synthesis of biological macromolecules such as amino acids, fatty acids, and nucleotides, and provide raw materials for the anabolism of tumor cells. In addition, the lactic acid produced by the glycolysis of tumor cells is released to the outside of the cell, forming a local acidic microenvironment, destroying the components of the extracellular matrix, and further enhancing the ability of tumor invasion and metastasis (101). Damaged mitochondria can also lead to abnormally active lipid metabolism and amino acid metabolism in tumor cells, providing raw materials for tumor cell survival and rapid proliferation (102, 103). Significantly increased levels of ROS in tumor cells are another feature of tumor cell metabolism. ROS are involved in many processes such as tumor cell transformation, proliferation, survival, migration, invasion, metastasis, and angiogenesis, and are closely related to the biological characteristics of tumor cells (104, 105). Mitochondrial dysfunction can lead to abnormal mitochondrial ROS homeostasis, resulting in the instability of the cell genome, tumor suppressor gene mutations, finally causing tumorigenesis (106). Mitochondria are both the main site of intracellular ROS generation and the main target of ROS attack. In the process of tumorigenesis, because mt DNA is not protected by histones and lacks the corresponding damage repair system, it is easy to be damaged by ROS and cause gene mutation. Mutations in mt DNA encoding proteins related to the oxidative phosphorylation system directly lead to the abnormality of the mitochondrial oxidative phosphorylation system, generating more ROS, which in turn aggravates further damage to mitochondrial function and ultimately drives the transformation of tumor cells into cell types that rely primarily on glycolysis for energy (107, 108). Besides the endoplasmic reticulum, mitochondria are another important intracellular calcium reservoir. Mitochondria can regulate intracellular calcium homeostasis through multiple calcium transport systems present on their membranes. Abnormal mitochondrial calcium homeostasis is closely related to mitochondrial dysfunction and the occurrence and development of tumors, but its specific mechanism is still unclear and needs to be further explored (109, 110). Decreased apoptotic capacity is one of the hallmarks of tumors. Apoptosis mainly includes two representative pathways, the mitochondrial apoptosis pathway and the death receptor-mediated apoptosis pathway. Mitochondria act as the regulatory center of apoptotic activity, and when mitochondrial apoptosis is inhibited, it may lead to tumor cells acquiring the ability to resist cell death (111, 112). Therefore, targeting the mitochondria to induce tumor cell apoptosis can be one of the strategies for tumor therapy. Mitophagy is a key adaptive effect of tumor cell survival by eliminating damaged mitochondria, controlling ROS production, reducing the risk of cell carcinogenesis, and reducing apoptosis (113, 114). Autophagy has dual regulatory effects on cell survival and death, and abnormal mitophagy is closely related to tumorigenesis. In addition, the impaired mitochondrial dynamic can lead to mitochondrial dysfunction, resulting in cell energy metabolism, proliferation, apoptosis, and mitophagy abnormal. The fusion and fission of mitochondria can also lead to changes in mitochondrial localization, which in turn affects the migration and invasion of tumor cells. Studies have found that key molecules involved in the regulation of mitochondrial fission and fusion, such as Drp1, MFN1, and MFN2, are abnormally expressed in a variety of tumor tissues, and may be closely related to tumor progression (115). The ability of tumor cells to migrate and invade is closely related to their ability to form pseudopodia, and the dynamic changes of microfilaments and microtubules involved in pseudopodia formation require a large amount of ATP generation. Therefore, as the main organ of ATP production, mitochondrial function, quantity and distribution can affect the formation of pseudopodia, which in turn affects the migration and invasion ability of tumor cells (116).

Research progress of berberine in antitumor by targeting the mitochondria

Mitochondria play an important role in abnormal energy metabolism, changes in ROS homeostasis, tissue infiltration and metastasis, and resistance to cell death in tumors. In recent years, with the in-depth study of the pharmacological mechanism of berberine, it has been found that berberine mainly achieves antitumor effects by interfering with tumor cell proliferation, inhibiting tumor cell invasion and metastasis, and inducing tumor cell apoptosis (117–119). At present, extensive in vitro experiments revealed that berberine can induce tumor cell apoptosis and inhibit tumor cell proliferation by regulating mitochondrial activity, thereby exerting antitumor pharmacological effects. Liu et al. revealed through metabolomics and transcriptomic studies that berberine can induce mitochondrial damage in pancreatic cancer cells, and may directly or indirectly interfere with the synthesis and expression of downstream fatty acids by targeting and regulating citrate metabolism and membrane transport in mitochondria, thereby inhibiting the growth of pancreatic cancer cells, promoting their apoptosis and inhibiting their invasion and metastasis (71). Sun et al. found that berberine-
induced oncosis of glioma cells was correlated with ATP depletion via the mitochondrial dysfunction induced by the inhibition of extracellular regulated protein kinases (ERK) activity. The down-regulation of mitochondrial phosphorylated extracellular regulated protein kinases (p-ERK) by berberine inhibited aerobic respiration and led to glycolysis, an inefficient energy production pathway (72). Prior studies have established that berberine could inhibit thyroid carcinoma cells by inducing mitochondrial apoptosis, G0/G1 cell cycle arrest and suppressing migration via phosphatidylinositol 3kinase (PI3K)-protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) signaling pathways (73). The mechanism of action of berberine in normal cells and tumor cells is similar such as regulating ROS. Oxidative stress plays an important role in the pathogenesis of many diseases. The beneficial effect of berberine is presumed to reside mostly in its antioxidant role (120). The mechanisms involved in the antioxidant role of berberine include scavenging ROS/RNS, removing free oxygen, reducing the destructiveness of superoxide ions and nitric oxide and so on. However, in tumor cells, berberine can increase the production of ROS and lead to the activation of the MAPK-p53 signaling pathway. The activated p53 and its downstream targets XAF1 and GADD45α interacted with PUMA, Bax and Bim in mitochondria, disrupted mitochondrial potential, and induced apoptosis in EBV+ B-lymphoma cells (74). Berberine can also induce mitochondrial dysfunction by significantly upregulating the expression of FoxO1 and FoxO3, thereby causing tumor cell apoptosis. Berberine significantly upregulated the mRNA expression of both FoxO1 and FoxO3α (75). FoxO transcription factors effectively heightened BH3-only protein Bim expression, and altered Bax/Bcl-2 ratio, culminating in mitochondrial dysfunction, caspases activation, and DNA fragmentation. Yan et al. found that berberine inhibited tumor growth and decreased mtDNA copy number of tumor cells in a dose-dependent manner in the HepG2 xenograft model, inhibiting cell proliferation (76).

Protect the cardiovascular system

The relationship between mitochondria and the development of cardiovascular disease

Cardiomyocyte mitochondria are the main site of cardiac energy metabolism, and their dysfunction can lead to a variety of cardiovascular diseases. Mitochondrial quality control mainly ensures the relative stability of mitochondrial morphology, quantity and quality by regulating mitochondrial biogenesis, fusion, fission and autophagy to maintain the integrity of its structure and function. Currently, numerous studies have confirmed that mitochondrial quality control plays an important role in cardiovascular diseases such as ischemic heart disease, heart failure, atherosclerosis, diabetic cardiomyopathy (DCM) and hypertension. Therefore, mitochondrial quality control in the early stage of disease and reducing mitochondrial dysfunction have become new targets for cardiovascular disease treatment.

Mitochondrial biogenesis directly affects mitochondrial quality control and further affects myocardial functional status. Mitochondrial biogenesis disorder is an early change in the development of heart failure. Cardiomyocytes are sites of high energy consumption, and improving mitochondrial biogenesis disorder has cardioprotective effects (121). Even though genetic and environmental factors are different, mitochondrial dynamics imbalance can still be observed in a variety of cardiovascular diseases, such as excessive mitochondrial fission or reduced mitochondrial fusion involved in the progression of myocardial ischemia/reperfusion (I/R) injury and atherosclerosis, suggesting the balance between mitochondrial fusion and fission plays a significant role in the normal heart development and function (122, 123). Therefore, mitochondrial fusion and fission proteins may provide new therapeutic targets for a variety of cardiovascular diseases. Under normal circumstances, mitophagy can maintain the stability of mitochondrial function in cells, thereby ensuring normal heart functioning, whereas abnormal mitophagy is closely related to a variety of cardiovascular diseases. Cardiomyocyte mitophagy is enhanced under various cardiovascular stresses, and whether mitophagy is a potential protective mechanism or a pathological mechanism leading to cell death or further disease development remains inconclusive. Some studies have reported that mitophagy has a protective effect on ischemic myocardium (124), but other studies have shown that mitophagy is one of the causes of myocardial I/R injury (125). Abnormality of the mitochondrial quality control system will lead to mitochondrial dysfunction. Growing research has proved that mitochondrial dysfunction is the cause of many cardiovascular diseases. Mitochondrial dysfunction plays an important role in the process of atherosclerosis by affecting normal lipid metabolism, increasing ROS production, stimulating inflammatory responses and vessel wall remodeling (126, 127). Mitochondrial energy metabolism disorder is an important factor in causing myocardial I/R injury. The main mechanisms include reduced mitochondrial ATP production and excessive ROS production, resulting in oxidative stress, Ca2+ overload and persistent mitochondrial PTR opening (128). Increased ROS, decreased ATP production, Ca2+ overload, and inhibition of mitochondrial electron transport chain caused by mitochondrial dysfunction play an important role in the occurrence and development of hypertension (129, 130). Mitochondrial energy metabolism disorder not only reduces mitochondrial ATP synthesis but also increases mitochondrial ROS generation, thus playing an important role in the occurrence and development of heart failure (131). The pathogenesis of DCM is complex. Hyperglycemia, lipid accumulation, oxidative stress, inflammation, myocardial fibrosis, cardiomyocyte apoptosis,
and mitochondrial damage are all involved in the pathophysiological process of DCM. Among them, mitochondrial damage caused by hyperglycemia leads to abnormal mitochondrial energy metabolism, increased ROS production, initiation of mitochondria-dependent apoptosis pathways, mitochondrial fission and fusion disorders, and changes in the content and structure of cardiolipin play a key role in the occurrence and development of DCM (132–134).

Research progress of berberine in protecting the cardiovascular system by targeting the mitochondria

Cardiovascular disease has become one of the diseases with the highest morbidity and mortality, and has received much attention in the world health system. With the continuous advancement of traditional Chinese medicine, a growing body of research has shown that traditional Chinese medicine has unique advantages in cardiovascular prevention and treatment. Berberine, as an active ingredient of the traditional Chinese medicine *Rhizoma Coptidis*, can regulate cardiovascular diseases such as hypertension, atherosclerosis, heart failure, DCM, ischemic heart disease, and arrhythmia by protecting vascular endothelial function, inhibiting inflammatory response, antiplatelet aggregation, dilating blood vessels, regulating autophagy, and anti-oxidation (135, 136).

Mitochondria are important targets for the treatment of cardiovascular disease. In recent years, with the deepening of the research on the pharmacological mechanism of berberine, it has been noticed that berberine can improve myocardial I/R injury, inhibit myocardial cell apoptosis, and protect cardiac function by regulating mitochondrial activity. *In vitro* experiments show that berberine could not only upregulate PTEN-induced putative kinase 1 (PINK1) and Parkin levels, activate the PINK1-Parkin signaling pathway, promote mitophagy, induce autophagic flux, reduce mitochondrial dysfunction, and improve myocardial I/R injury, but also can promote mitophagy, reduce myocardial enzyme activity, induce cardiomyocyte proliferation, inhibit cardiomyocyte apoptosis, and protect the heart from myocardial I/R injury, possibly through the hypoxia-inducible factor 1α (HIF-1α)/BNIP3 pathway (77, 78). Studies have shown that doxorubicin (DOX) could rapidly induce mitochondrial damage and increase intracellular AMP/ATP ratio, which in turn activates AMPK phosphorylation and promotes cardiomyocyte apoptosis. Lv et al. reported that berberine suppressed DOX-induced cardiomyocyte apoptosis via protecting mitochondria (reducing DOX-induced loss of mitochondrial membrane potential), reducing the increased ratio of AMP to ATP and inhibiting AMPK phosphorylation as well as elevating Bcl-2 expression in the early stage of DOX treatment (79). Hang et al. proposed that berberine could prevent high glucose-induced cardiomyocyte hypertrophy by activating the AMPK signaling pathway to inhibit mitochondrial fission, upregulating proliferator-activated receptor-gamma coactivator 1α (PGC1α) to stimulate mitochondrial biosynthesis, and restoring autophagic flux disturbance (80). Animal experiments confirmed that berberine activated mitophagy via the PINK1/Parkin pathway and protected cardiac function in pressure overload-induced heart failure (81).

Other pharmacological effects

Berberine has a wide range of pharmacological effects and can be applied to various diseases. In addition to hypoglycemic, lipid-lowering, cardiovascular protection, and antitumor effects, berberine also has pharmacological activities such as anti-inflammatory, antibacterial, and protection of the central nervous system. In recent years, a large number of studies have shown that berberine targeting the mitochondria as therapeutic targets to regulate the structure and function of mitochondria, thereby exerting pharmacological effects. Yu et al. found that berberine pretreatment had a protective effect on hypoxia/reoxygenation-induced apoptosis in human kidney proximal tubular cells, and the mechanism was related to the inhibition of mitochondrial stress and endoplasmic reticulum stress pathways (86). Liu et al. reported that berberine suppresses influenza virus-triggered NOD-like receptor pyrin domain-containing protein 3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS (82). Li et al. found that berberine attenuated the cytotoxicity induced by tert-butyl hydroperoxide via inhibiting oxidative stress and mitochondria dysfunction in PC-12 cells (83). Berberine significantly suppressed cytochrome c expression, upregulated the ratio of Bcl-2/Bax, and ameliorated mitochondrial dysfunction by optimizing mitochondria membrane potential status and ATP production, playing a protective role in anti-apoptotic and anti-oxidative stress. Zhao et al. reported that berberine protected against Aβ-induced axonal mitochondrial abnormalities in primary cultured hippocampal neurons by preserving the mitochondrial membrane potential and ATP generation, increasing axonal mitochondrial density and length, and improving mitochondrial motility and trafficking, ultimately preventing synaptic loss (84). Previous research indicated that berberine activates AMPK in peripheral neurons and neuronal cells, which promotes PGC-1α-mediated mitochondrial biogenesis, and augments autophagy to promote mitochondrial function (85). The improved mitochondrial function by berberine further strengthened redox homeostasis through stimulation of endogenous antioxidant systems and inhibition of neuroinflammation. These effects lead to increased nerve conduction velocity, improved nerve blood flow, and decreased hyperalgesia in diabetic neuropathy. Teodor et al. found that mitochondria isolated from the livers of high-fat-fed rats exhibited decreased calcium accumulation capacity and impaired oxidative phosphorylation capacity, such as impaired mitochondrial...
membrane potential, oxygen consumption, and cellular ATP levels, whereas berberine could reverse liver mitochondrial dysfunction in high-fat-fed rats by upregulating mitochondrial SIRT3 activity (87). Tian et al. proposed that berberine improved the cognitive impairment caused by diabetic encephalopathy by inhibiting the Rho/Rho kinase (ROCK) pathway in diabetic encephalopathy rats, increasing mitochondrial membrane potential and reducing ROS levels (88).

Summary and outlook

Mitochondria are ubiquitous organelles that mainly consist of a bilayer-membrane structure and matrix. It is the ‘power station’ of cells and plays a core role in cell energy production, metabolism and signal transmission. Notably, mitochondria are critical for respiration, apoptosis, and mitochondrial DNA inheritance, and alterations in their structural and functional integrity may lead to ATP depletion, ROS overproduction, decreased mitochondrial membrane potential, impaired mtDNA and other mitochondrial dysfunction, and further mediate cell apoptosis and inflammatory responses (137). The mitochondrial quality control system mainly includes mitochondrial biosynthesis, dynamics and autophagy. As an important endogenous mechanism for maintaining mitochondrial homeostasis in cells, the mitochondrial quality control system has two opposites. It not only involves the regeneration of mitochondria, but also includes the removal of damaged or aging mitochondria, which is the core of maintaining the normal mitochondrial structure and exerting the normal physiological function of mitochondria (138). Recent studies have suggested that mitochondria are the target organelles for many drugs and poisons. Berberine is a common active ingredient in a variety of heat-clearing and detoxifying traditional Chinese medicines. Its functions such as heat-clearing and detoxifying and antibacterial have been used in clinical practice, and it also has various pharmacological activities such as antitumor, hypoglycemic, blood lipid regulation, hypotensive and antiarrhythmic effects. With more in-depth research, the mechanism of berberine’s pharmacological activity by targeting the mitochondria has been elucidated. Berberine can affect the quality control and function of mitochondria to a certain extent by regulating the expression of oxidative stress, mitochondrial fusion and fission, mitophagy, mitochondrial biosynthesis, and intracellular calcium regulation, thereby exerting pharmacological effects.

In improving glycolipid metabolism disorder, berberine can directly inhibit mitochondrial respiratory chain complex I or regulate the function of mitochondrial respiratory chain complex I by inhibiting SIRT3 in the mitochondrial matrix, thereby inhibiting ATP synthesis, upregulating the ratio of AMP/ATP, activating the AMPK signaling pathway to inhibit hepatic glycogen production, promote glycolysis, and improve insulin sensitivity. Berberine can also improve mitochondrial dysfunction, regulate mitochondrial energy homeostasis, and then regulate glycolipid metabolism disorder by promoting the expression of PGC-1α and upregulating mitochondrial biosynthesis, inhibiting the expression and mitochondrial translocation of Drp1 and downregulating mitochondrial fission. In antitumor progression, berberine can induce tumor cell apoptosis by activating PI3K-AKT and MAPK-p53 signaling pathways or promoting the expression of FoxO1 and FoxO3, and upregulating pro-apoptotic proteins such as Bax and Bim. Berberine also exerts antitumor effect by inhibiting cell proliferation by inhibiting ERK activity and inducing mitochondrial dysfunction or reducing mtDNA copy number. In the prevention and treatment of cardiovascular diseases, berberine mainly protects cardiac function by activating the PINK1-Parkin, HIF-1α/BNIP3 signaling pathways and promoting mitophagy. In addition, berberine can also improve mitochondrial function by protecting mitochondrial membrane potential, activating mitochondrial apoptosis signaling pathway, and promoting mitochondrial biogenesis, thereby exerting pharmacological effects such as anti-inflammatory and nerve protection. In summary, berberine mainly regulates the function of the mitochondrial respiratory chain, activates the important energy homeostasis regulator AMPK, regulates glycolipid metabolism, regulates mitochondrial apoptosis, promotes tumor cell apoptosis, promotes mitophagy to reduce mitochondrial dysfunction and protect heart function.

Mitochondria are important targets for berberine to exert its pharmacological effects, but the regulatory mechanism of berberine on mitochondria still needs to be further studied. Firstly, there are differences in mitochondria and their functions in different species. Different concentrations and dosages of berberine affect the regulation of mitochondria. Therefore, in order to prevent differences in research results, the research design should be more standardized. Secondly, the relevant research is still at an exploratory stage, and the research types mainly are animal experiments or cell experiments, and lack of in vivo mitochondrial experiments or clinical trials to evaluate the mechanism of action. Most importantly, there is currently a lack of multi-target, multi-path, multi-dimensional, and in-depth systematic research. Current research mostly focuses on the regulation of a specific pathway, the detection indicators are relatively limited, and pharmacokinetics is lacking. In addition, mitochondrial quality control is a continuous dynamic process, and static assessment of the roles and mechanisms of independent components of the mitochondrial quality control system at a single time point may generate research bias. Therefore, it is necessary to further explore the influence mechanism on different signaling pathways and their related factors in the process of applying berberine to intervene in mitochondria in the treatment of diseases. The normal maintenance of cell activity and physiological function relies on the cooperation of multiple intracellular and extracellular...
molecules and signaling pathways, and mitochondria are extensively involved in the regulation of physiological activities. Consequently, we need to comprehensively explore the mechanism of berberine regulating mitochondria to exert pharmacological effects through different technical means and different signal transduction pathways. The application of emerging omics technologies and methods such as mitochondrial proteomics and epigenetics is expected to bring light to screen and discover the targets of berberine.

Author contributions

JT developed the review question. The initial literature review was performed by XF. The first draft of the manuscript was written by XF with all authors commenting on subsequent versions of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (81904187), Capital Health Development Research Project (CD2020-4-4155), CACMS Outstanding Young Scientific and Technological Talents Program (ZZ13-YQ-026), CACMS Innovation Fund (C12021A01601), and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity. Chin Med (2018) 13:13. doi: 10.1186/s41382-018-0171-3

Acknowledgments

We would like to thank all the authors for their contribution to the realization of this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Habtemariam S. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol Res (2020) 155:104722. doi: 10.1016/j.phrs.2020.104722

2. Rabbaniani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and vibrio cholerae. J Infect Dis (1987) 155(5):797–84. doi: 10.1093/infdis/155.5.797

3. Rajasekhar K, Samanta S, Bagoband V, Murugan NA, Govindarajus T. Antioxidant berberine-derivative inhibits multifaceted amyloid toxicity. Science (2020) 23(4):101005. doi: 10.1126/sciadv.abb5245

4. Meng FC, Wu ZF, Yin ZQ, Lin LG, Wang R, Zhang QW. Coptidis rhizoma and its metabolites after oral administration in rats. J Pharm Sci (2010) 99(4):1105–10. doi: 10.1016/j.xphs.2010.01.055

5. Kheir MM, Wang Y, Hua L, Hu J, Lei F, et al. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol (2010) 48(4):1105–10. doi: 10.1016/j.fct.2009.12.014

6. Zuo F, Nakamura N, Ako T, Hatton M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos (2006) 34(12):2064–72. doi: 10.1124/dmd.04/011361

7. Battu SK, Reka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S. Physicochemical characterization of berberine clathrate: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech (2010) 11(3):1466–75. doi: 10.1208/s12249-010-9520-y

8. Zhang YT, Yu YQ, Yan XX, Wang WJ, Tian XT, Wang L, et al. Different structures of berberine and five other protoberberine alkaloids that affect p-glycoprotein-mediated efflux capacity. Acta Pharmacol Sin (2019) 40(1):133–42. doi: 10.1038/s41401-018-0183-7

9. Han Y, Yang X, Shi Y, Tang X, Pan L, Gao J, et al. Pharmacokinetics and pharmacological activities of berberine in diabetes mellitus treatment. Evid Based Complement Alternat Med (2021) 2021:9987097. doi: 10.1155/2021/9987097

10. Tan XS, Ma JY, Feng R, Ma C, Chen WJ, Sun YP, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One (2013) 8(10):e79769. doi: 10.1371/journal.pone.0079769

11. Ma BL, Ma YM, Shi R, Wang TM, Zhang N, Wang CH, et al. Identification of the toxic constituents in rhizoma coptidis. J Ethnopharmacol (2010) 128(2):357–64. doi: 10.1016/j.jep.2010.01.047

12. Zhang X, Zhang X, Wang C, Li Y, Dong L, Cui L, et al. Neuroprotection of early and short-time applying berberine in the acute phase of cerebral ischemia: up-regulated pAkt, pGSK and pCREB, down-regulated NF-κB expression, accelerated BBB permeability. Brain Res (2012) 1459:61–70. doi: 10.1016/j.brainres.2012.03.065

13. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos (2010) 38(10):1779–84. doi: 10.1124/dmd.110.039396

14. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep (2015) 5:12155. doi: 10.1038/srep12155

15. Ma JY, Feng R, Tan XS, Ma C, Shou JW, Fu J, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci (2013) 102(11):4181–92. doi: 10.1002/jps.23718

16. Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, et al. Berberine in cardiovascular and metabolic diseases: From mechanisms to therapeutics. Theranostics (2019) 9(7):1923–51. doi: 10.7150/thno.30787
17. Wang H, Liu D, Cao P, Lecker S, Hu Z. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes (2010) 59(6):1879–89. doi: 10.2337/db10-0207

18. Kysensius K, Brunello CA, Huttenen HJ. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One (2014) 9(4):e91729. doi: 10.1371/journal.pone.0091729

19. Chan E. Displacement of bcl-xL from albumin by berberine. Biol Neonate (1993) 63(4):201–8. doi: 10.1159/000243932

20. Zhi D, Feng PG, Sun JL, Guo F, Zhang R, Zhao X, et al. The enhancement of cardiac toxicity by concomitant administration of berberine and macrolides. Eur J Pharm Sci (2015) 76:149–55. doi: 10.1016/j.ejps.2015.05.009

21. Fang P, Zhao L, Guo F, Zhang B, Feng L, Zhu M, et al. The enhancement of cardiotoxicity that results from inhibition of CYP3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact (2018) 293:115–23. doi: 10.1016/j.cbi.2018.07.022

22. Kiriya Y, Nochi H. Intra- and intercellular quality control mechanisms of mitochondria. J Cell Biol (2014) 203(7):637–47. doi: 10.1083/jcb.2100011

23. Liesa M, Palacin M, Zorzan A. Mitochondrial dynamics in mammalian health and disease. Physiol Rev (2009) 89(3):799–845. doi: 10.1152/physrev.00030.2008

24. Yu SB, Pekker Z. Mechanisms orchestrating mitochondrial dynamics for energy homoeostasis. J Mol Biol (2018) 430(21):3922–41. doi: 10.1016/j.jmb.2018.07.027

25. Leson OC, Song Z, Chen H, Chan DC. Fis1, mff, Mtd49, and Mtd51 mediate Drp1 recruitment in mitochondrial fission. Mol Cell Biol (2013) 24(9):6599–67. doi: 10.1128/MCB.01072-11

26. Frohlich C, Grabger S, Schwedel F, Faeltl K, Rosenbaum E, Meurs J, et al. Structural insights into oligomerization and mitochondrial remodelling of dynamin-1-like protein. EMBO J (2013) 32(9):1280–92. doi: 10.1002/embj.201303774

27. Ji WK, Hatch AL, Merrill RA, Strack S, Higgs HN. Actin filaments target the oligomeric maturation of the dynamin GTPase Drp1 to mitochondrial fission sites. Elife (2015) 4:e11553. doi: 10.7554/eLife.11553

28. Smirnova E, Gricarpiz L, Shurland DL, van der Bliek AM. Dynamin-related proteins and mitochondrial fusion. EMBO J (2015) 34(1):50–e1. doi: 10.1525/embj.2014413447

29. Cao YL, Meng S, Chen Y, Feng JX, Gu DD, Yu B, et al. MFN1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion. EMBO J (2014) 33(2):224–36. doi: 10.1002/embj.201303245

30. Rudka T, et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion sites. EMBO J (2017) 36(7):765–77. doi: 10.1525/embj.201692242

31. Zhi D, Feng PF, Sun JL, Guo F, Zhang R, Zhao X, et al. The enhancement of mitophagy through a novel mitophagy receptor-mediated pathway. Mol Cell (2014) 54(3):362–77. doi: 10.1016/j.molcel.2014.02.034

32. Chen Z, Liu L, Cheng Q, Li Y, Wu H, Zhang W, et al. Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to fine-tune hynpic mitophagy. EMBO Rep (2017) 18(3):495–509. doi: 10.15252/embr.201643389

33. Murakawa T, Yamaguchi O, Hashimoto A, Hikoso S, Takeda T, Oka T, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat Commun (2015) 6:7527. doi: 10.1038/ncomms8527

34. Bhujabal Z, Biggidoit AB, Spietttem E, Brenne HB, Øvervatn A, Habisov S, et al. FKBPF recruits LC3A to mediate parkin-independent mitophagy. EMBO Rep (2017) 18(6):947–61. doi: 10.15252/embr.201643417

35. Arndt T, Soares F, Tattoli I, Castanier C, Philpot DJ, Girardin SE. An n-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. J Cell Sci (2009) 122(17):3161–8. doi: 10.1242/jcs.051932

36. Zhang Y, Yao Y, Qu X, Wang G, Hu Z, Chen S, et al. Listeria hijacks host mitochondria through a novel mitophagy receptor to evade killing. Nat Immunol (2019) 20(4):433–46. doi: 10.1038/s41590-019-0324-2

37. Weng Y, Chung WC, Sumpter RM, Mishra P, Levine B. Prohibitin 2 is an inner mitochondrial membrane mitophagy receptor. Cell (2017) 168(1-2):224–38.e10. doi: 10.1016/j.cell.2016.11.042

38. Schlattner U, Tokarska-Schlattner M, Rousseau D, Boissain M, Mannella C, Epand R, et al. Mitochondrial cardiolipin/phospholipid trafficking: the role of membrane contact site complexes and lipid transfer proteins. Chem Phys Lipids (2017) 194-195:21–31. doi: 10.1016/j.chemphyslip.2017.12.008

39. Chu CT, Ji J, Kang DG, Kang JF, Tyurina YY, Kaprolav AA, et al. Mitochondrial cardiolipin/phospholipid-mediated externalization to the outer mitochondrial membrane as an elimination signal for mitophagy in neuronal cells. Nat Cell Biol (2013) 15(10):1197–205. doi: 10.1038/ncc3837

40. Kagan VE, Jiang D, Huang Z, Tyurina YY, Desbordes C, Cottet-Rousselle C, et al. NIPDK-p (NM23-H4)-mediated externalization of cardiolipin enables elimination of depolarized mitochondria by mitophagy. Cell Death Dis (2016) 7(3):1140–51. doi: 10.1038/cddis.2015.160

41. Lehmann JJ, Bargr PM, Kovacs A, Saffiez JE, Medetos DM, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest (2000) 106(7):847–56. doi: 10.1172/JCI2006

42. Weinberg JM. Mitochondrial biogenesis in kidney disease. J Am Soc Nephrol (2011) 22(3):431–6. doi: 10.1681/ASN.2010060443

43. Zhang Q, Wu Y, Zhang P, Sha H, Ji J, Hu Y, et al. Exercise induces mitochondrial biogenesis after brain ischemia in rats. Neuroscience (2012) 205:10–7. doi: 10.1016/j.neuroscience.2011.12.053

44. Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. J Neurovi Sci (2017) 95(1):1025–9. doi: 10.1016/j.jnrs.2017.02.015

45. Islam H, Edgett BA, Gurd BJ. Coordination of mitochondrial biogenesis by PGC-1α in human skeletal muscle: A re-evaluation. Metabolism (2018) 79:42–51. doi: 10.1016/j.metabol.2017.11.001

46. Wu Z, Puigserver P, Andersson U, Zhang C, Ademant G, Mootha V, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell (1999) 98(1):115–24. doi: 10.1016/S0092-8674(99)08011-X

47. Xu M, Xiao Y, Yin J, Hou W, Yu X, Shen L, et al. Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS One (2014) 9(7):e103702. doi: 10.1371/journal.pone.0103702

48. Turner N, Li Y, Goosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes (2008) 57(5):1441–8. doi: 10.2337/db07-1152

49. Zhang B, Pan Y, Xu L, Tang D, Dorfman RG, Zhou Q, et al. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SRT3. Endocrine (2018) 62(3):576–87. doi: 10.1007/s12020-018-1697-y
regulation of XAF1 and GADD45α.

4. Hao Q, Wu P, Liu W, Chen L, Xu H, et al. Berberine induces mitophagy and decreasing mitochondrial ROS.

5. Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, et al. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun (2014) 5:5493.

6. Xu X, Zhu XP, Bai JY, Xia P, Li Y, Lu Y, et al. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.

7. Fang et al. 10.3389/fendo.2022.982145 (2017) 9:1225 via glomerular podocytes.

8. Br J Pharmacol (2020) 11:253.

9. Qin X, Jiang M, Zhao Y, Gong J, Su H, Yuan F, et al. Berberine protects against diabetic kidney disease by inducing autophagic dysfunction and increasing bcl-2 expression.

10. In vitro regulating the mitophagy-mediated HIF-1α.

11. JBC (2012) 7:41712. doi:10.1038/srep41712.

12. Berberine protects against chronic kidney disease in mice by activating SIRT3.

13. Berberine reverts hepatic mitochondrial dysfunction in high-fat fed rats: a possible role for SIRT3 activation.

14. Berberine is a novel therapeutic target for dyslipidemia.

15. Berberine ameliorates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3.

16. Berberine suppresses influenza virus-triggered NLRP3 inflammasome activation in macrophages by inducing mitophagy and decreasing mitochondrial ROS.

17. J Leukoc Biol (2020) 108 (1):253–66. doi: 10.1002/jlb.MA0302-358RR
104. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discovery* (2009) 8(7):579–91. doi:10.1038/nrd2803

105. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. *Antioxid Redox Signal* (2012) 16 (11):1299–322. doi:10.1089/ars.2011.4141

106. Rottenberg H, Hoek JB. The path from mitochondrial ROS to aging runs through the mitochondrial permeability transition pore. *Aging Cell* (2017) 16 (5):943–55. doi:10.1111/ace.12650

107. Carew JS, Huang P. Mitochondrial defects in cancer. *Mol Cancer* (2002) 1:9–19. doi:10.1186/1476-4598-1-9

108. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. *Science* (2008) 320(5876):661–4. doi:10.1126/science.1156906

109. Ren T, Wang J, Zhang H, Yuan P, Zhu J, Wu Y, et al. MUC1-mediated mitochondrial calcium signaling facilitates cell survival of hepatocellular carcinoma via reactive oxygen species-dependent PT3 degradation. *Antioxid Redox Signal* (2012) 17(28):1120–36. doi:10.1089/ars.2017.6990

110. Huang Q, Cao H, Zhan L, Sun X, Wang G, Li J, et al. Mitochondrial fission forms a positive feedback loop with cytosolic calcium signaling pathway to promote autophagy in hepatocellular carcinoma cells. *Cancer Lett* (2017) 403:108–18. doi:10.1016/j.canlet.2017.05.034

111. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. *Cell Death Differ* (2006) 13(8):1396–402. doi:10.1038/sj.cdd.4401963

112. Adams MS, Letali A. Targeting the b-cell lymphoma/leukemia 2 family in cancer. *J Clin Oncol* (2012) 30(23):3127–35. doi:10.1200/JCO.2011.37.0981

113. Lu Z, Miao Y, Muhammad I, Tian E, Hu W, Wang J, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-dependent permeabilization during apoptosis: the innocent bystander scenario. *Cell Death Differ* (2016) 24(2):180–90. doi:10.1038/s41419-017-0011

114. Lo AK, Lung RW, Dawson CW, Young LS, Ko CW, Yeung WW, et al. Activation of sterol regulatory element-binding protein 1 (SREBP1) mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma. *J Pathol* (2014) 233(1):99–104. doi:10.1002/path.4587

115. Huang Q, Zhan L, Cao H, Li J, Lyu Y, Guo X, et al. Increased mitochondrial fission protects the heart against ischemia/reperfusion injury. *Circulation* (2013) 128(24):2462–73. doi:10.1161/CIRCULATIONAHA.113.003518

116. Liu J, Jiang Z, Jiang J, Yu M, Xie Y, Huang Y, Wolf DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. *Oncogene* (2013) 32(40):4814–24. doi:10.1038/onc.2012.494

117. Izuka N, Miyamoto K, Okita K, Tangok A, Hayashi H, Yosino S, et al. Inhibitory effect of coptidis rhizoma and berberine on the proliferation of human esophageal cancer cell lines. *Cancer Lett* (2000) 148(1):19–25. doi:10.1016/s0304-3835(99)00264-5

118. Ho YT, Yang JS, Li TC, Lin JJ, Lin JG, Lai KC, et al. Inhibiting mitochondrial calcium signaling protects mice from increased uncoupled respiration and activation of uncoupling proteins. *Cardiovasc Res* (2008) 80(1):30–9. doi:10.1093/cvr/cvn184

119. Bosca MG, Vanquez EJ, Kerner J, Parlard W, Chandler MP, Stanley W, et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. *Cardiovasc Res* (2008) 80(1):30–9. doi:10.1093/cvr/cvn184

120. Boudina S, Sena S, Theohald H, Sheng X, Wright JJ, Hu X, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. *Diabetes* (2007) 56(10):2457–66. doi:10.2337/db07-0481

121. Yu T, Shen SS, Robothan JL, Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. *Cardiovasc Res* (2008) 79(2):341–51. doi:10.1093/cvr/cvn104

122. Li B, Zheng Z, Wei Y, Wang M, Peng J, Kang T, et al. Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. *Cardiovasc Diabetol* (2011) 10:69. doi:10.1186/1475-2840-10-69

123. Tan HL, Chan KG, Puspajarih P, Duangkajorn S, Saokaew S, Mehmood Khan T, et al. Mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases. *Pharmacol Res* (2021) 165:105433. doi:10.1016/j.phrs.2021.105433
Glossary

| Abbreviation | Description |
|--------------|-------------|
| ADP          | adenosine diphosphate |
| AKT          | protein kinase B |
| AMP          | adenosine monophosphate |
| AMPK         | adenosine 5’monophosphate-activated protein kinase |
| ATP          | adenosine triphosphate |
| Bcl-2        | BH3-only subfamily of B cell lymphoma-2 |
| Bcl2L13      | Bcl-2-like protein 13 |
| BNIP3        | Bcl-2/adenovirus E1B 19 kDa interacting protein 3 |
| β-OX         | β-oxidation |
| CI           | cardiolipin |
| DCM          | diabetic cardiomyopathy |
| DFCP1        | double FYVE containing protein 1 |
| D KD         | diabetic kidney disease |
| DOX          | doxorubicin |
| Drp1         | dynamin-related protein1 |
| ERK          | extracellular regulated protein kinases |
| Fis1         | fission protein 1 |
| FKBP8        | FK506 binding protein 8 |
| FUNDC1       | FUN14 domain-containing protein 1 |
| GLP-1        | glucagon-like peptide-1 |
| hERG         | human ether-a-go-go-related gene |
| HFD          | high-fat diet |
| HIF-1αr      | hypoxia-inducible factor 1α |
| IMM          | inner mitochondrial membrane |
| I/R          | ischemia/reperfusion |
| LCAD         | long-chain acyl-CoA dehydrogenase |

(Continued)